Bone Medical Limited (ASX:BNE) announced that patients have received their first doses in the oral CaPTHymone(PTH) Phase I/II clinical trial carried out at Q-Pharm, Brisbane, Australia.
Bone Medical Limited (ASX:BNE) announced that patients have received their first doses in the oral CaPTHymone(PTH) Phase I/II clinical trial carried out at Q-Pharm, Brisbane, Australia.